PT - JOURNAL ARTICLE AU - Marra, Valerio AU - Quartin, Miguel TI - A Bayesian estimate of the COVID-19 infection fatality ratio in Brazil based on a random seroprevalence survey AID - 10.1101/2020.08.18.20177626 DP - 2021 Jan 01 TA - medRxiv PG - 2020.08.18.20177626 4099 - http://medrxiv.org/content/early/2021/02/11/2020.08.18.20177626.short 4100 - http://medrxiv.org/content/early/2021/02/11/2020.08.18.20177626.full AB - We infer the infection fatality ratio (IFR) of SARS-CoV-2 in Brazil by combining three datasets. We compute the prevalence via the population-based seroprevalence survey EPICOVID19-BR. For the fatalities we obtain the absolute number using the public Painel Coronavírus dataset and the age-relative number using the public SIVEP-Gripe dataset. The time delay between the development of antibodies and subsequent fatality is estimated via the SIVEP-Gripe dataset. We obtain the IFR via Bayesian inference for each survey stage and 27 federal states. We include the effect of fading IgG antibody levels by marginalizing over the time after contagion at which the test gives a negative result with a flat prior on the interval [40, 80] days. We infer a country-wide average IFR (maximum posterior and 95% CI) of 0.97% (0.82–1.14%) and age-specific IFR: 0.028% (0.024–0.036%) [< 30 years], 0.21% (0.17–0.25%) [30–49 years], 1.06% (0.88–1.31%) [50–69 years], 2.9% (2.5–3.7%) [≥ 70 years].Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was provided.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and codes used for this work are made publicly available. https://github.com/mquartin/covid19-ifr-br